Pulmatrix's Grant - II Round

Pulmatrix raised a round of funding on November 23, 2009. Investors include National Institute of Allergy and Infectious Diseases.

Pulmatrix is a clinical stage biotechnology company with an inhaled dry powder platform advancing a new generation of inhaled therapeutics. The platform, called iSPERSE (inhaled small particles easily…

Articles about Pulmatrix's Grant - II Round: